ASX · ACW.AX
Actinogen Medical Limited
A$0.04-A$0.00 (-4.65%)
Actinogen Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 43.06% below the high.
Loading market information…
ASX · ALA.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 03:05 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Arovella Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 47.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Arovella Therapeutics Limited’s next earnings report is currently expected on Feb 25, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Arovella Therapeutics Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 |
|---|
| Aug 31, 2023 |
| -A$0.01 |
| A$26.31K |
| Q2 2023 | Feb 22, 2023 | -A$0.01 | A$379.59K |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.04-A$0.00 (-4.65%)
Actinogen Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 43.06% below the high.
A$0.11-A$0.01 (-4.35%)
Alcidion Group Limited’s quoted price sits in the lower half of its reported 52-week range, 24.14% below the high.
A$0.35+A$0.02 (+4.55%)
Recce Pharmaceuticals Ltd’s quoted price sits in the lower half of its reported 52-week range, 52.74% below the high.
A$0.30-A$0.03 (-8.46%)
Island Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 52.78% below the high.
A$0.36A$0.00 (0.0%)
Biome Australia Limited’s quoted price sits in the upper half of its reported 52-week range, 26.53% below the high.
A$0.26-A$0.00 (0.0%)
Alterity Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 66.88% below the high.
A$0.08-A$0.01 (-5.62%)
Amplia Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 69.45% below the high.
A$0.04-A$0.00 (-7.89%)
Imugene Limited’s quoted price sits in the lower half of its reported 52-week range, 91.46% below the high.
